Abstract
Tolvaptan sodium phosphate (Samtas®; Otsuka Pharmaceutical, Tokyo, Japan) is a newly
available intravenous aquaretic diuretic (commercially available from May 2022), which
acts as an arginine vasopressin V2 receptor antagonist. Thus far, optimal patient
selection as well as safety and efficacy in real-world practice remain unknown. We
experienced two patients with congestive heart failure treated with tolvaptan sodium
phosphate. In one patient with right-sided heart failure, oral tolvaptan was converted
to intravenous tolvaptan sodium phosphate, and another one with right and left-sided
heart failure and impaired swallowing function received intravenous tolvaptan sodium
phosphate on a de novo basis. Following the initiation of tolvaptan sodium phosphate,
their congestive symptoms ameliorated immediately without any complications. Tolvaptan
sodium phosphate may be safe and effective in real-world practice, although further
studies are warranted to establish optimal patient selection and clinical management.
Learning objective
We report here an initial experience of newly-introduced intravenous tolvaptan sodium
phosphate in real-world practice. The novel medication might be particularly suitable
for those with severe thirst, congestive gut edema, or requiring rapid amelioration
of systemic/pulmonary congestion, although further accumulating experiences are warranted
to establish optimal therapeutic strategy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiology CasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version.Circ J. 2019; 83: 2084-2184
- 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J. 2021; 42: 3599-3726
- Diuretic resistance in heart failure.Curr Heart Fail Rep. 2019; 16: 57-66
- Real-world effectiveness and tolerability of tolvaptan in patients with heart failure - final results of the samsca post-marketing surveillance in heart failure (SMILE) study.Circ J. 2019; 83: 1520-1527
- Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan.ESC Heart Fail. 2021; 8: 527-528
- Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure - a phase II, multicenter, double-blind, randomized, active-controlled trial.Circ J. 2022; 86: 699-708
- Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.ESC Heart Fail. 2022; 9: 3275-3286
- Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF) - a phase III, multicenter, open-label trial.Circ J. 2022; 86: 1068-1078
- Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients–association between non-responders and chronic kidney disease.Circ J. 2013; 77: 397-404
- Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure.Int J Mol Sci. 2016; 17: 105
Article info
Publication history
Published online: January 06, 2023
Accepted:
December 9,
2022
Received in revised form:
November 12,
2022
Received:
October 4,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
